FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285403786> ?p ?o ?g. }

• W4285403786 endingPage "101022" @default.
• W4285403786 startingPage "101022" @default.
• W4285403786 abstract "Systemic, immune, and target therapies are growing in use in the management of metastatic cancers. The aim of this review was to describe up-to-date published data on the safety and tolerability of metastasis-directed hypofractionated radiation therapy (RT) when combined with newer systemic, immune, and targeted therapies and to provide suggested strategies to mitigate potential toxicities in the clinical setting.A comprehensive search was performed for the time period between 1946 and August 2021 using predetermined keywords describing the use of noncentral nervous system palliative RT with commonly used targeted systemic therapies on PubMed and Medline databases. A total of 1022 articles were screened, and 130 met prespecified criteria to be included in this review.BRAF and MEK inhibitors are reported to be toxic when given concurrently with RT; suspension 3 days and 1 to 2 days, respectively, prior and post-RT is suggested. Cetuximab, erlotinib/gefitinib, and osimertinib were generally safe to use concomitantly with conventional radiation. But in a palliative/hypofractionated RT setting, suspending cetuximab during radiation week, erlotinib/gefitinib 1 to 2 days, and osimertinib ≥2 days pre- and post-RT is suggested. Vascular endothelial growth factor inhibitors such as bevacizumab reported substantial toxicities, and the suggestion is to suspend 4 weeks before and after radiation. Less data exist on sorafenib and sunitinib; 5 to 10 days suspension before and after RT should be considered. As a precaution, until further data are available, for cyclin-dependent kinase 4-6 inhibitors, consideration of suspending treatment 1 to 2 days before and after RT should be given. Ipilimumab should be suspended 2 days before and after RT, and insufficient data exist for other immunotherapy agents. Trastuzumab and pertuzumab are generally safe to use in combination with RT, but insufficient data exist for other HER2 target therapy.Suggested approaches are described, using up-to-date literature, to aid clinicians in navigating the integration of newer targeted agents with hypofractionated palliative and/or ablative metastatic RT. Further prospective studies are required." @default.
• W4285403786 created "2022-07-14" @default.
• W4285403786 creator A5017021482 @default.
• W4285403786 creator A5054471183 @default.
• W4285403786 creator A5059043243 @default.
• W4285403786 creator A5064127595 @default.
• W4285403786 creator A5072488977 @default.
• W4285403786 creator A5075315276 @default.
• W4285403786 date "2022-11-01" @default.
• W4285403786 modified "2023-10-11" @default.
• W4285403786 title "Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies" @default.
• W4285403786 cites W1215179222 @default.
• W4285403786 cites W1490756663 @default.
• W4285403786 cites W1494828436 @default.
• W4285403786 cites W1526227760 @default.
• W4285403786 cites W1533390250 @default.
• W4285403786 cites W1769017264 @default.
• W4285403786 cites W1926958054 @default.
• W4285403786 cites W1969790467 @default.
• W4285403786 cites W1972081093 @default.
• W4285403786 cites W1975721268 @default.
• W4285403786 cites W1976228480 @default.
• W4285403786 cites W1979044635 @default.
• W4285403786 cites W1979811833 @default.
• W4285403786 cites W1983853242 @default.
• W4285403786 cites W1990549345 @default.
• W4285403786 cites W1995805135 @default.
• W4285403786 cites W1995903912 @default.
• W4285403786 cites W2017731821 @default.
• W4285403786 cites W2025798292 @default.
• W4285403786 cites W2030227571 @default.
• W4285403786 cites W2031121223 @default.
• W4285403786 cites W2046435071 @default.
• W4285403786 cites W2046871776 @default.
• W4285403786 cites W2056734912 @default.
• W4285403786 cites W2059453816 @default.
• W4285403786 cites W2059719338 @default.
• W4285403786 cites W2068596197 @default.
• W4285403786 cites W2087864906 @default.
• W4285403786 cites W2092862243 @default.
• W4285403786 cites W2096597725 @default.
• W4285403786 cites W2097813654 @default.
• W4285403786 cites W2098981947 @default.
• W4285403786 cites W2099356406 @default.
• W4285403786 cites W2107539838 @default.
• W4285403786 cites W2108923852 @default.
• W4285403786 cites W2116901818 @default.
• W4285403786 cites W2124640278 @default.
• W4285403786 cites W2127189800 @default.
• W4285403786 cites W2128260490 @default.
• W4285403786 cites W2131625550 @default.
• W4285403786 cites W2139483106 @default.
• W4285403786 cites W2144848856 @default.
• W4285403786 cites W2151730005 @default.
• W4285403786 cites W2153321830 @default.
• W4285403786 cites W2155530710 @default.
• W4285403786 cites W2157501935 @default.
• W4285403786 cites W2161105029 @default.
• W4285403786 cites W2162186306 @default.
• W4285403786 cites W2165311092 @default.
• W4285403786 cites W2170161732 @default.
• W4285403786 cites W2170242096 @default.
• W4285403786 cites W2170366300 @default.
• W4285403786 cites W2170893313 @default.
• W4285403786 cites W2172026555 @default.
• W4285403786 cites W2177996735 @default.
• W4285403786 cites W2221304580 @default.
• W4285403786 cites W2292435599 @default.
• W4285403786 cites W2337433988 @default.
• W4285403786 cites W2342434791 @default.
• W4285403786 cites W2397918955 @default.
• W4285403786 cites W2461739654 @default.
• W4285403786 cites W2471585592 @default.
• W4285403786 cites W2515622316 @default.
• W4285403786 cites W2521278016 @default.
• W4285403786 cites W2587330058 @default.
• W4285403786 cites W2588177826 @default.
• W4285403786 cites W2588718083 @default.
• W4285403786 cites W2601822576 @default.
• W4285403786 cites W2605371223 @default.
• W4285403786 cites W2618641368 @default.
• W4285403786 cites W2728032424 @default.
• W4285403786 cites W2736561915 @default.
• W4285403786 cites W2740037107 @default.
• W4285403786 cites W2749991799 @default.
• W4285403786 cites W2751602305 @default.
• W4285403786 cites W2753065806 @default.
• W4285403786 cites W2757215022 @default.
• W4285403786 cites W2759495409 @default.
• W4285403786 cites W2766460973 @default.
• W4285403786 cites W2766613591 @default.
• W4285403786 cites W2768978641 @default.
• W4285403786 cites W2774283417 @default.
• W4285403786 cites W2778861299 @default.
• W4285403786 cites W2787553571 @default.
• W4285403786 cites W2789601009 @default.
• W4285403786 cites W2790015936 @default.
• W4285403786 cites W2805209851 @default.

• next